Abevmy Drug Interactions

No clinically relevant interaction of co-administered chemotherapy on bevacizumab (Reference Product) pharmacokinetics was observed. No clinically relevant interaction of bevacizumab (Reference Product) was observed on the pharmacokinetics of co-administered interferon alpha 2a, erlotinib (or its active metabolite OSI-420), or the chemotherapies irinotecan (and its metabolite SN384), capecitabine, oxaliplatin, and cisplatin.
In patients with NSCLC, there was no apparent difference in the mean exposure of either carboplatin or paclitaxel, when each was administered alone or in combination with bevacizumab (Reference Product).
In some patients with mRCC, treated with bevacizumab (Reference Product) in combination with sunitinib malate microangiopathic haemolytic anaemia (MAHA) was reported; MAHA was fully reversible upon discontinuation of bevacizumab (Reference Product) and sunitinib malate.
No studies investigating the interaction of anti-EGFR antibodies and bevacizumab have been conducted. Observations suggest increased toxicity with concomitant use of anti-EGFR antibodies compared to bevacizumab plus chemotherapy alone.
Interactions between bevacizumab and radiotherapy have not been established. EGFR monoclonal antibodies should not be administered for the treatment of mCRC in combination with bevacizumab-containing chemotherapy.